Effcacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy: Meta-analysis and clinical implications

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 48, Issue 2, 2017, Pages 160-166

  Khan, Zainab ^a   Kuriakose, Robin K ^b   Khan, Maryam ^a   Chin, Eric K ^c   Almeida, David R P ^d  

^a QUEEN S UNIVERSITY   (Canada)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Retina Consultants of Southern California   (United States)

^d VitreoRetinal Surgery PA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MESOGLYCAN; VASCULOTROPIN INHIBITOR; DELAYED RELEASE FORMULATION; DRUG IMPLANT; GLUCOCORTICOID; VASCULOTROPIN A;

ADULT; ARTICLE; BEST CORRECTED VISUAL ACUITY; CONTROL GROUP; DIABETIC MACULAR EDEMA; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HUMAN; IMPLANT; MEASUREMENT; META ANALYSIS; OPHTHALMOLOGICAL THERAPEUTIC DEVICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUSTAINED DRUG RELEASE; SYSTEMATIC REVIEW; TREATMENT DURATION; VISION; ANTAGONISTS AND INHIBITORS; COMPLICATION; DELAYED RELEASE FORMULATION; DIABETIC RETINOPATHY; DRUG IMPLANT; DRUG RESISTANCE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; TREATMENT OUTCOME;

DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85014919176     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20170130-10     Document Type: Article

References (33)

1. No authors listed. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthal-mol. 1985;103(12):1796-1806.
2. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609-614.
3. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello L P, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-1077.
4. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for dia-betic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119(4):789-801.
5. Bayer. VEGF Trap-Eye in Vision Impairment Due to DME (VIVID-DME). ClinicalTrials.gov identifer NCT01331681. https://clinical-trials.gov/ct2/show/NCT01331681. Published April 17, 2011. Updated March 20, 2016.
6. Bayer. Study of Intravitreal Administration of VEGF Trap-Eye (BAY86-5321) in Patients With Diabetic Macular Edema (VISTA DME). ClinicalTrials.gov identifer NCT01363440. https://clinical-trials.gov/ct2/show/NCT01363440. Published May 27, 2011. Updated April 25, 2016.
7. Diabetic Retinopathy Clinical Research Network, Wells JA, Glass-man AR, et al. Afibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.
8. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular ede-ma. Ophthalmology. 2012;119(8):1658-1665.
9. Stewart MW. The expanding role of vascular endothelial growth fac-tor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87(1):77-88.
10. Nguyen QD, Shah SM, Van Anden E, Sung JU, Vitale S, Campo-chiaro PA. Supplemental oxygen improves diabetic macular edema: A pilot study. Invest Ophthalmol Vis Sci. 2004;45(2):617-624.
11. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992;110(8):1155-1159.
12. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizum-ab for diabetic macular edema. Am J Ophthalmol. 2011;152(4):686-694.
13. Campochiaro PA, Brown DM, Pearson A, et al. Long-term beneft of sustained-delivery fuocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626-635.
14. Tas M, Oner V, Alakus M F, Türkcü FM, Iscan Y, Yüksel K. Single injection of triamcinolone versus three repeated injections of beva-cizumab for treatment of diabetic macular edema. Int Ophthalmol. 2013;33(4):375-380.
15. Gan IM, Ugahary LC, van Dissel JT, van Meurs JC. Effect of intra-vitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol. 2005;243(11):1186-1189.
16. Chan CK, Mohamed S, Lee VY, Lai TY, Shanmugam M P, Lam DS. Intravitreal dexamethasone for diabetic macular edema: A pilot study. Ophthalmic Surg Lasers Imaging. 2010;40(1):26-30.
17. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): Development and validation of a new instrument. ANZ J Surg. 2003;73(9):712-716.
18. Ramu J, Yang Y, Menon G, et al. A randomized clinical trial comparing fxed vs pro-renata dosing of Ozurdex in refractory diabetic macu-lar oedema (OZDRY study). Eye (Lond). 2015;29(12):1603-1612.
19. Alshahrani ST, Dolz-Marco R, Gallego-Pinazo R, et al. Intravitreal dexamethasone implant for the treatment of refractory macular edema in retinal vascular diseases: Results of the KKESH International Collaborative Retina Study Group. Retina. 2016;36(1):131-136.
20. Yoon YH, Boyer DS, Belfort R Jr., et al. Long-term effcacy and safety of dexamethasone intravitreal implant in phakic and pseudophakic eyes with diabetic macular edema. Investigative Ophthalmology & Visual Science. 2014;55:1779-1779.
21. Escobar-Barranco JJ, Pina-Marín B, Fernández-Bonet M. Dexameth-asone implants in patients with naïve or refractory diffuse diabetic macular edema. Ophthalmologica. 2015;233(3-4):176-185.
22. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014;231(3):141-146.
23. Totan Y, Güler E, Güragaç FB. Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevaci-zumab treatment. Curr Eye Res. 2016;41(1):107-113.
24. Rishi P, Rishi E, Kuniyal L, Mathur G. Short-term results of intra-vitreal dexamethasone implant (OZURDEX) in treatment of recalcitrant diabetic macular edema: A case series. Oman J Ophthalmol. 2012 May;5(2):79-82.
25. Zalewski D, Raczynska D, Raczynska K. Five-month observation of persistent diabetic macular edema after intravitreal injection of Ozur-dex implant. Mediators Infamm. 2014;2014:364143.
26. Haller JA, Bandello F, Belfort R Jr., et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-1146.e3.
27. Pacella E, Vestri AR, Muscella R, et al. Preliminary results of an intra-vitreal dexamethasone implant (Ozurdex) in patients with persistent diabetic macular edema. Clin Ophthalmol. 2013;7:1423-1428.
28. Boyer DS, Yoon YH, Belfort R Jr., et al. Three-year, randomized, sh-am-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914.
29. Bansal P, Gupta V, Gupta A, Dogra MR, Ram J. Effcacy of Ozurdex implant in recalcitrant diabetic macular edema-a single-center experience. Int Ophthalmol. 2016;36(2):207-216.
30. Lei S, Wai-Ching L. Effcacy and safety of dexamethasone intravitreal implant for refractory macular edema in children. Can J Ophthalmol. 2015;50(3):236-241.
31. Guigou S., Hajjar C, Parrat E, et al. [Multicenter Ozurdex assessment for diabetic macular edema: MOZART study]. J Fr Ophtalmol. 2014;37(6):480-485.
32. Scaramuzzi M, Querques G, Spina CL, Lattanzio R, Bandello F. Re-peated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. Retina. 2015;35(6):1216-22.
33. Dugel PU, Bandello F, Loewenstein A. Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol. 2015;9:1321.